Industry Leader Thermo Fisher's Contract Services Positioned For Growth Amid Popular Demand For GLP-1 Weight Loss Drugs, Analyst Initiates With Long-Term Growth Potential
Industry Leader Thermo Fisher's Contract Services Positioned For Growth Amid Popular Demand For GLP-1 Weight Loss Drugs, Analyst Initiates With Long-Term Growth Potential
Thermo Fisher has around 18% share of the estimated total addressable market at more than $235 billion.Stephens initiated coverage on Thermo Fisher Scientific (NYSE:TMO) and cited the company as an industry leader in the broader life science tools/services/ diagnostics industry, with fiscal year 2023 sales of almost $42.9 billion.
Stephens對賽默飛世爾（紐交所：TMO）進行了覆蓋，並稱該公司是更廣泛的生命科學工具/服務/診斷行業的行業領導者，2023財年銷售額近429億美元。
The analyst highlights Thermo Fisher's extensive product and service portfolio and its significant revenue base. Over the past decade, the company has expanded its presence in the biopharma sector through strategic mergers and acquisitions, enhancing its market exposure.
分析師強調賽默飛世爾廣泛的產品和服務組合以及其可觀的營業收入基礎。在過去的十年裏，該公司通過戰略性併購擴大了在生物製品領域的影響力，增強了市場曝光。
Also Read: Thermo Fisher Q2 Earnings: Marginal Revenue Dip, Completes Olink Acquisition, Lifts Annual Profit Outlook.
另請參閱：賽默飛世爾第二季度收益：營業收入略有下降，完成Olink收購，提高年度利潤展望。
Thermo Fisher has around 18% share of the estimated total addressable market at more than $235 billion.
賽默飛世爾約佔估計總可尋址市場的18%，超過2350億美元。
Stephens says disciplined M&A strategy and organic growth opportunities have the potential to support a long runway for long-term growth and margin expansion.
Stephens表示，謹慎的併購策略和有機增長機會有可能支持長期增長和利潤擴張的良好前景。
Thermo Fisher's pharma services assets, especially its contract development and manufacturing organization (CDMO), are well positioned in today's market. The company is set to capitalize on growth opportunities in the injectables sector, driven by GLP-1 demand, and in biologics drug substance production, supported by the BIOSECURE bill.
賽默飛世爾的製藥服務資產，尤其是其合同開發和製造組織（CDMO），在今天的市場中處於有利位置。該公司將利用注射劑領域的增長機會，受到GLP-1需求的推動，以及生物製品藥物物質生產領域的增長機會，得到《生物安全法案》的支持。
Stephens analyst writes, "After a difficult couple of years for the broader LS tools complex, 2025 should be a better year, but we have tried to assume a gradual recovery in our estimates."
Stephens分析師寫道：「在過去幾年對更廣泛的生命科學工具複雜系統的困難時期後，2025年應會更好，但我們已經嘗試在我們的估算中假設逐漸恢復。」
Stephens initiated coverage with an Overweight rating and a price target of $680.
Stephens以超配評級進行了覆蓋，並設定了680美元的價格目標。
The company's Practical Process Improvement (PPI) system fosters ongoing enhancements and plays a crucial role in realizing synergies from acquisitions.
公司的實際流程改進（PPI）系統促進持續改進，並在實現併購協同效應方面發揮關鍵作用。
However, pursuing larger mergers and acquisitions may face greater challenges due to Thermo Fisher's large scale and the heightened scrutiny of an active Federal Trade Commission.
然而，由於賽默飛世爾規模龐大和聯邦貿易委員會的高度審查，追求更大型的併購可能面臨更大挑戰。
Despite this, Thermo Fisher's diverse portfolio offers ample organic growth potential, and there are still M&A opportunities, particularly in bioprocessing, cell and gene therapy markets, and related service areas, per the analyst.
儘管如此，賽默飛世爾多元化的投資組合提供了豐富的有機增長潛力，而且根據分析師的說法，在生物加工、電芯和基因療法市場以及相關服務領域仍存在併購機遇。
Price Action: TMO stock is down 0.83% at $613.45 at last check Tuesday.
股價走勢：TMO股價在上週二最後確認爲613.45美元，下跌0.83%。
- Qualcomm Partners With STMicroelectronics To Boost AI-Powered IoT Connectivity.
- 高通與意法半導體合作，以增強基於人工智能的物聯網連接。
譯文內容由第三人軟體翻譯。
